{"id":"intravitreal-methotrexate-400-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Cataract"},{"rate":null,"effect":"Retinal toxicity"},{"rate":null,"effect":"Vitreous inflammation"},{"rate":null,"effect":"Corneal epitheliopathy"},{"rate":null,"effect":"Elevated intraocular pressure"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that blocks dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and DNA/RNA synthesis. Direct intravitreal administration delivers high local concentrations to the vitreous cavity while minimizing systemic exposure, making it suitable for treating intraocular lymphomas and other vitreous malignancies. The drug's antiproliferative effects target rapidly dividing lymphoid cells.","oneSentence":"Intravitreal methotrexate is a chemotherapy agent injected directly into the eye that inhibits dihydrofolate reductase, suppressing DNA synthesis and reducing proliferation of malignant cells in ocular lymphomas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:50.438Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary central nervous system lymphoma with vitreous involvement"},{"name":"Intraocular lymphoma"}]},"trialDetails":[{"nctId":"NCT05392179","phase":"PHASE2","title":"A Study in Subjects With Retinitis Pigmentosa","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2022-07-14","conditions":"Retinitis Pigmentosa","enrollment":8},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravitreal Methotrexate 400 µg","genericName":"Intravitreal Methotrexate 400 µg","companyName":"JHSPH Center for Clinical Trials","companyId":"jhsph-center-for-clinical-trials","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravitreal methotrexate is a chemotherapy agent injected directly into the eye that inhibits dihydrofolate reductase, suppressing DNA synthesis and reducing proliferation of malignant cells in ocular lymphomas. Used for Primary central nervous system lymphoma with vitreous involvement, Intraocular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}